- Home
- CALY vs HCM Comparison
CALY vs HCM Comparison
Compare CALY & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CALY | HCM |
|---|---|---|
| Founded | 1982 | 2000 |
| Country | United States | Hong Kong |
| Employees | 30000 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CALY | HCM |
|---|---|---|
| Price | $14.01 | $14.53 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $17.00 | $13.75 |
| AVG Volume (30 Days) | ★ 3.3M | 22.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $48.29 | N/A |
| Revenue Next Year | N/A | $16.12 |
| P/E Ratio | $64.24 | ★ $5.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.26 | $11.51 |
| 52 Week High | $16.65 | $19.50 |
Technical Indicators
Market Signals| Indicator | CALY | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 47.54 | 41.92 |
| Support Level | $13.76 | $14.15 |
| Resistance Level | $15.14 | $14.63 |
| Average True Range (ATR) | 0.70 | 0.43 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 54.63 | 12.96 |
Price Performance
Historical ComparisonAbout CALY Callaway Golf Company
Callaway Golf Co is a golf equipment, gear and apparel company with a portfolio of world-wide brands, including Callaway Golf, Odyssey, TravisMathew, and OGIO. Callaway designs, manufactures, and sells high-performance golf clubs, golf balls, apparel, bags, and other accessories-setting the standard for performance in the game of golf.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.